Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $205
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has maintained an Outperform rating on Ascendis Pharma and raised its price target from $191 to $205, indicating a positive outlook for the company's stock.
September 17, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group has maintained an Outperform rating on Ascendis Pharma and increased the price target from $191 to $205, suggesting a positive short-term outlook for the stock.
The increase in the price target from $191 to $205 by Evercore ISI Group, along with the maintained Outperform rating, indicates a strong positive sentiment from analysts. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100